Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Zymeworks Inc.NASDAQ: ZYME
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of $42.74M rose 203.1% year over year, behind the +24248.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 121.0% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Selling, general & admin amounted to 58.0% of revenue in FY2025, down 22.6 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $273.25M (+344.3%) for the fiscal year ending Dec 2026, a step up from the +0.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $42.74M+121.0% QoQ
- Last fiscal yearDec 2025
- $61.5M+0.0% YoY
- LTMSep 2026
- $15.14B+24248.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 61.5M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +9.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.5M | +0.0% |
| FY2024 | 2024-12-31 | 61.5M | -12.6% |
| FY2023 | 2023-12-31 | 70.4M | -4.1% |
| FY2022 | 2022-12-31 | 73.4M | +72.3% |
| FY2021 | 2021-12-31 | 42.6M | — |
Selling, General & Admin vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 selling, general & admin of $15.14B is the highest of the 11 companies compared; the peer median is $44.73M.
- Its year-over-year change of +24248.6% is the highest of 11, against a peer median of +13.4%.
- Selling, general & admin amounts to 5694.1% of revenue for ZYME, versus a peer median of 74.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.14B | +24248.6% | -5.7% | 5694.1% | |
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Jun 2026 | $65.29M | +5.1% | +10.3% | 62.2% | |
| LTM Sep 2026 | $64.15M | +52.3% | +47.5% | — | |
| LTM Sep 2026 | $51.3M | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $31.1M | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $29.66M | +100.0% | +10.0% | 249.6% | |
| LTM Mar 2026 | $21.28M | -23.4% | -6.3% | — | |
| LTM Mar 2026 | $9.36M | -6.3% | -5.7% | 12.9% | |
| Peer median (excluding ZYME) | $44.73M | +13.4% | +10.0% | 74.8% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.